RIGL Q2 2020 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+53.9% YoY

Gross Profit

$16M98.3% margin

Operating Income

-$17M-108.6% margin

Net Income

-$18M-109.7% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

-71.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$138M

Total Liabilities

$75M

Stockholders' Equity

$63M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$10M	+53.9%
Gross Profit	$16M	$10M	+55.9%
Operating Income	-$17M	-$21M	+18.5%
Net Income	-$18M	-$21M	+14.7%

Revenue Segments

Gross Product

$18M57%

Product

$15M47%

Research And Development Services And Others

$1M3%

Contract Revenues From Collaborations

$1M3%

Discounts And Allowances

-$3M-11%